A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 (HORIZON)
An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of Delandistrogene Moxeparvovec Following Plasmapheresis in Subjects With Duchenne Muscular Dystrophy and Pre-existing Antibodies to AAVrh74
Sponsor: Sarepta Therapeutics, Inc.
Terminated
Study is being terminated due to a business decision.
Other terminated trials from Sarepta Therapeutics, Inc.
- Limb Girdle Muscular Dystrophy · Phase PHASE1 · Jun 2025
- Limb Girdle Muscular Dystrophy · Phase PHASE1 · Jun 2025
- Duchenne Muscular Dystrophy · Phase PHASE2 · Feb 2025
- Limb-Girdle Muscular Dystrophy, Type 2E · Phase PHASE1/PHASE2 · Jan 2025
- Duchenne Muscular Dystrophy · Phase PHASE3 · Jul 2023
More terminations from Sarepta Therapeutics, Inc.
Other Duchenne Muscular Dystrophy trials with similar outcome
Listed as NCT06597656, this PHASE1 trial focuses on Duchenne Muscular Dystrophy and remains terminated or withdrawn. Sponsored by Sarepta Therapeutics, Inc., it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Apr 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .